Jefferies Initiates Coverage On Amicus Therapeutics with Buy Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
Jefferies has initiated coverage on Amicus Therapeutics with a Buy rating and set a price target of $18.
September 06, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has initiated coverage on Amicus Therapeutics with a Buy rating and a price target of $18, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target by a reputable firm like Jefferies is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100